Thierry Van Nieuwenhove, CEO of Quotient Sciences recognises that sustainability and resilience are critical to the future of pharmaceutical development supply chains.
As an industry, we must balance the need for innovation and speed with responsible environmental stewardship.
Our ESG commitments at Quotient are deeply embedded in our mission to accelerate the development of new medicines while minimising our environmental impact.
A key example of this is our flagship drug development platform, Translational Pharmaceutics, which integrates formulation development, on-demand GMP manufacturing and clinical testing.
This streamlined approach accelerates drug development while significantly reducing the amount of active pharmaceutical ingredient (API) required.
By minimising material waste and energy consumption, Translational Pharmaceutics helps to lower the environmental footprint of drug development.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.Featured companies
Ecolab Life Sciences
Ecolab Life Sciences is the market leader in the supply of premier contamination control solutions for life science cleanrooms worldwide.
Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small-molecule and peptide drug...
- Companies:
- Recipharm
- Axplora
- CordenPharma
- Sharp Clinical Services
- Mabion